Astec LifeSciences achieved strong FY26 revenue of ₹453.22 Cr, significantly cutting losses to ₹(80.88) Cr.

Astec LifeSciences LimitedASTEC · Filed with the exchange

A ₹249.35 Cr rights issue was completed, and credit ratings remained robust (ICRA AA- long-term, A1+ short-term). Strategic focus on CDMO and efficiency continues.

Read the original filing(PDF)

No comments yet. Be the first.

More from Astec LifeSciences Limited

All announcements

Updates11-09-2026
Price movement
Updates09-09-2026
Spurt in Volume
Dividend/Bonus14-08-2026
Record Date Updates
Others01-08-2026
Copy of Newspaper Publication
Others01-08-2026
Copy of Newspaper Publication
Others31-07-2026
Others

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.